Atrophic Vaginitis: An Undertreated Epidemic, Part I CME/CE

Author Information and Disclosures

Release Date: July 18, 2008; Valid for credit through July 18, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.5 nursing contact hours (0.25 contact hours are in the area of pharmacology)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME/CE Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Novo Nordisk
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Review the diagnosis and treatment of atrophic vaginitis
  2. Evaluate options for treating atrophic vaginitis, with a specific focus on associated benefits and risks
  3. Describe ways to facilitate evidence-based decision making concerning treatment choices for patients with atrophic vaginitis
Authors and Disclosures

Raquel D. Arias, MD
Disclosure: Raquel D. Arias, MD, has disclosed that she has served as a consultant to Barr/Duramed, Bayer, Novo Nordisk, Novogyne, Pfizer, Upsher-Smith, and Wyeth.


Andrew M. Kaunitz, MD
Disclosure: Andrew M. Kaunitz, MD, has disclosed that he owns stock, stock options, or bonds in Procter & Gamble and sanofi-aventis. Dr. Kaunitz has also disclosed that he has received grants for clinical research from Barr/Duramed and Bayer. Dr. Kaunitz has also disclosed that he has served as an advisor or consultant to Barr/Duramed, Bayer, and Noven Pharmaceuticals.


Michael L. Krychman, MD, FACOG
Disclosure: Michael L. Krychman, MD, FACOG, has disclosed that he has served as an advisor or consultant to Wyeth Pharmaceutical.


Peggy Keen, PhD, FNP
Disclosure: Peggy Keen, PhD, FNP, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.